TScan Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of TScan Therapeutics generated cash of -$61,358,000, which is more than the previous year. Cash used in financing activities reached the amount of $135,443,000 last year. Net change in cash is therefore $13,326,000.
Cash Flow
| 2019 | -12.52M | -1.24M | 34.81M |
|---|---|---|---|
| 2020 | -3.02M | -4.23M | 288K |
| 2021 | -48.67M | -9.94M | 189.66M |
| 2022 | -66.50M | -4.22M | 29.35M |
| 2023 | -61.35M | -60.75M | 135.44M |
TCRX Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 125.06M | 166.43M | 35.38M | 42.35M | 21.31M |
Operating activities | |||||
Net income | -89.21M | -66.22M | -48.62M | -26.12M | -13.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 5.36M | 5.13M | 3.32M | 1.23M | 519K |
Stock-based compensation expense | 5.20M | 4.55M | 2.51M | 515K | 240K |
| Deferred income tax benefit | 5.20M | 4.55M | 2.51M | 515K | 240K |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -52K | 528K | 10K | 1.12M | 161K |
Cash generated by operating activities | -61.35M | -66.50M | -48.67M | -3.02M | -12.52M |
Investing activities | |||||
Purchases Of Investments | -77.61M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.14M | -4.22M | -9.94M | -4.23M | -1.24M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -60.75M | -4.22M | -9.94M | -4.23M | -1.24M |
Financing activities | |||||
Common Stock Issued | 42.41M | 193K | 89.64M | 288K | 34.81M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 29.35M | 0 | 0 | 0 |
Cash used in financing activities | 135.44M | 29.35M | 189.66M | 288K | 34.81M |
Net Change In Cash | 13.32M | -41.37M | 131.05M | -6.97M | 21.04M |
Cash at end of period | 138.39M | 125.06M | 166.43M | 35.38M | 42.35M |
| Data source | Data source | Data source |